Chitogel has developed a bioresorbable hydrogel technology that improves surgical outcomes and patient wellbeing after functional endoscopic sinus surgeries. Developing a compound which has several clinically proven benefits from a derivative of chitosan, Chitogel demonstrates anti-inflammatory properties and the ability to modulate wound healing within the nasal passage, helping to prevent a range of adverse events and complications in post surgery sites.

Originally developed at the University of Otago, the company has a strong patent portfolio and regulatory profile. Already in clinical use and distributed by Medtronics, Chitogel has seen adoption by clinical practitioners both nationally and in the USA. Chitogel has continuously grown their national and international market share, quickly dominating the Aotearoa New Zealand market and are on track to see multi-million dollar deal flow from the company’s international sales channels in the next two to three years.